Keytruda approved for the treatment of advanced melanoma
the ONA take:
The U.S. Food and Drug Administration has approved Merck & Co.'s Keytruda (pembrolizumab) for the treatment of patients with advanced melanoma who have been previously treated with ipilimumab. Pembrolizumab is of a new class of medications that target the programmed cell death 1 (PD-1) receptor.
Results of the study that lead to the approval of Keytruda were presented at the American Society of Clinical Oncology (ASCO) annual meeting earlier this year. Of 411 patients enrolled in the study, 221 had previously received ipilimumab, while 190 had not. The study tested pembrolizumab at three different dosing schedules: 10 mg/kg every 3 weeks, 2 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks. Of those enrolled in the study, 28% of those previously treated with ipilimumab experienced a response, while 40% of those not previously treated with ipilimumab had a response at 6 months or more.
Researchers found a median progression-free survival of 23 weeks for those previously treated with ipilimumab and 24 weeks for those that had not been. Furthermore, about 90% of patients did not experience side effects and only 4% discontinued the drug due to adverse effects.
The FDA has approved Keytruda for the treatment of patients with advanced melanoma.
Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
The Food and Drug Administration said it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another melanoma drug called Yervoy. Experts called the news "game-changing" for patients with the deadly skin cancer, which is becoming more common and kills nearly 10,000 Americans each year.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|